全球克隆氏症治疗市场规模、份额、趋势和成长分析报告（2026-2034）

克隆氏症治疗市场预计将从 2025 年的 183.8 亿美元成长到 2034 年的 245.4 亿美元，2026 年至 2034 年的复合年增长率为 3.26%。

随着发炎性肠道疾病（IBD）在全球范围内的日益流行，克隆氏症治疗药物的全球市场正经历着稳定成长。克隆氏症是一种慢性疾病，会导致胃肠道炎症，需要长期药物治疗。人们对胃肠道疾病的认识不断提高，以及诊断技术的进步，都促进了对有效治疗方法的需求成长。

该市场的主要驱动力之一是先进生物製药和标靶治疗方法的进步。製药公司正致力于开发能够减轻发炎并改善患者生活品质的创新药物。此外，医疗保健成本的上升和获得专业医疗服务的机会增加也是推动先进治疗方法的重要因素。

未来几年，随着免疫学研究与开发以及生物製药研发的不断进步，克隆氏症治疗市场预计将迎来强劲成长。包括生物相似药和个人化治疗方案在内的新治疗方法的引入，有望改善治疗效果。患者意识的提高和医疗基础设施的改善也将进一步推动全球市场的扩张。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球克隆氏症治疗市场：按类型划分

• 市场分析、洞察与预测
• 非手术治疗（抗发炎药、免疫抑制剂、抗生素等）
• 手术治疗

第五章：全球克隆氏症治疗市场：依给药途径划分

• 市场分析、洞察与预测
• 注射药物
• 口服

第六章：全球克隆氏症治疗市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第七章 全球克隆氏症治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • AbbVie Inc
  • Perrigo Company Plc
  • Pfizer Inc
  • Johnson & Johnson Services Inc
  • Ferring BV
  • Bristol-Myers Squibb Company（Celgene Corporation）
  • F. Hoffmann-La Roche Ltd（Genentech Inc.）
  • UCB SA
  • Salix Pharmaceuticals
  • Gilead Sciences Inc

The Crohn's Disease Treatment Market size is expected to reach USD 24.54 Billion in 2034 from USD 18.38 Billion (2025) growing at a CAGR of 3.26% during 2026-2034.

The global Crohn's disease treatment market is experiencing steady growth due to the increasing prevalence of inflammatory bowel diseases (IBD) worldwide. Crohn's disease is a chronic condition that causes inflammation in the digestive tract and requires long-term medical management. Growing awareness about gastrointestinal disorders and improved diagnostic techniques are contributing to the rising demand for effective treatment options.

One of the major drivers of this market is the increasing development of advanced biologic therapies and targeted treatment approaches. Pharmaceutical companies are focusing on developing innovative drugs that can reduce inflammation and improve patient quality of life. Additionally, rising healthcare expenditure and better access to specialized healthcare services are supporting the adoption of advanced treatment options.

In the coming years, the Crohn's disease treatment market is expected to witness strong growth as research in immunology and biologic drug development continues to advance. The introduction of novel therapies, including biosimilars and personalized treatment approaches, is likely to improve treatment outcomes. Increasing patient awareness and improved healthcare infrastructure will further contribute to the expansion of this market globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Non-SurgicalA (Anti-Inflammatory, Immune System Suppressors, Antibiotics, Others)
• Surgical

By Route of Administration

• Injectable
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Takeda Pharmaceutical Company Limited, , AbbVie Inc, Perrigo Company plc, Pfizer Inc, Johnson Johnson Services Inc, Ferring BV, BristolMyers Squibb Company Celgene Corporation, F HoffmannLa Roche Ltd Genentech Inc, UCB SA, Salix Pharmaceuticals, Gilead Sciences Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CROHN'S DISEASE TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Non-Surgical (Anti-Inflammatory, Immune System Suppressors, Antibiotics, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Surgical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CROHN'S DISEASE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CROHN'S DISEASE TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CROHN'S DISEASE TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CROHN'S DISEASE TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 AbbVie Inc
  • 9.2.2 Perrigo Company Plc
  • 9.2.3 Pfizer Inc
  • 9.2.4 Johnson & Johnson Services Inc
  • 9.2.5 Ferring B.V
  • 9.2.6 Bristol-Myers Squibb Company (Celgene Corporation)
  • 9.2.7 F. Hoffmann-La Roche Ltd (Genentech Inc.)
  • 9.2.8 UCB S.A
  • 9.2.9 Salix Pharmaceuticals
  • 9.2.10 Gilead Sciences Inc